Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol and Nicotine Patch for Smoking Cue Reactivity
NCT05587361Phase 4Recruiting
- Sponsor
- University of Oklahoma
- Start
- Nov 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of propranolol in Tobacco Use Disorder (TUD) and nicotine dependence (4 arms), sponsored by University of Oklahoma. Primary endpoints: Cue-Provoked Craving Ratings, Blood-Oxygen Level Dependent (BOLD) Activation to Smoking Cues and 4 more. Started Nov 2024; status: recruiting.
02
Drugs
propranolol
03
Conditions
Tobacco Use Disorder (TUD)nicotine dependence
Beyond the preview
Go deeper on NCT05587361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05587361.